Moderna says late-stage trial shows its COVID-19 vaccine is nearly 95 percent effective

COVID-19 vaccines
(Image credit: Screenshot/YouTube/AP)

Moderna announced early Monday that, according to preliminary phase-three trial data reviewed by an independent monitoring board, its coronavirus vaccine candidate was more than 94 percent effective. CEO Stéphane Bancel called the results a "game-changer." Among the trial's 30,000 participants, 90 COVID-19 cases were found among those getting placebo shots, and only five cases occurred among those who got the two-dose vaccine. Moderna also said doses of its vaccine, once thawed, could last at refrigerated temperatures for a longer-than-expected 30 days.

The vaccine's preliminary 94.5 percent efficacy is a "really important milestone," Moderna president Dr. Stephen Hoge told The Associated Press. But more importantly, the fact that both it and Pfizer's vaccine had similar results "should give us all hope that actually a vaccine is going to be able to stop this pandemic and hopefully get us back to our lives." The company said it expects to seek emergency authorization use from the Food and Drug Administration by early December, once more data has come in.

Subscribe to The Week

Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

SUBSCRIBE & SAVE
https://cdn.mos.cms.futurecdn.net/flexiimages/jacafc5zvs1692883516.jpg

Sign up for The Week's Free Newsletters

From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.

From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.

Sign up
Explore More
Peter Weber, The Week US

Peter has worked as a news and culture writer and editor at The Week since the site's launch in 2008. He covers politics, world affairs, religion and cultural currents. His journalism career began as a copy editor at a financial newswire and has included editorial positions at The New York Times Magazine, Facts on File, and Oregon State University.